Publication:
Antiangiogenic Molecules Suppressed Meningioma-Induced Neovascularization: A Corneal Angiogenesis Study

Simple item page
dc.contributor.authorTatarlı, Necati
dc.contributor.authorCeylan, Davut
dc.contributor.authorOksal, Muhammed Deniz
dc.contributor.authorAvşar, Timuçin
dc.contributor.authorKilic, Turker D.
dc.contributor.institutionTatarlı, Necati, Department of Neurosurgery, University of Health Sciences, Istanbul, Turkey
dc.contributor.institutionCeylan, Davut, Department of Neurosurgery, Sakarya Üniversitesi, Serdivan, Turkey
dc.contributor.institutionOksal, Muhammed Deniz, Neuroscience Program, Bahçeşehir Üniversitesi, Istanbul, Turkey
dc.contributor.institutionAvşar, Timuçin, Department of Biology, Bahçeşehir Üniversitesi, Istanbul, Turkey
dc.contributor.institutionKilic, Turker D., Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, Turkey
dc.date.accessioned2025-10-05T15:22:57Z
dc.date.issued2022
dc.description.abstractAIM: To investigate the angiogenic effects of bevacizumab and imatinib on different meningioma tissue grades. MATERIAL and METHODS: In this study, in silico analysis of angiogenesis-related gene expression was carried out using previously reported datasets. Messenger ribonucleic acid expressions of VEGFA, VEGFB, PDGFRA, and PDGFRB genes were obtained from two different meningioma transcriptome datasets. The effect of antiangiogenic drugs, bevacizumab and imatinib, on meningiomainduced vascularization was assessed by using rat corneal angiogenesis assay (CAA). RESULTS: Bevacizumab and imatinib both significantly reduced meningioma-induced neovascularization in the CAA model. CONCLUSION: The angiogenic characteristics of meningiomas may be suppressed by using antiangiogenic drugs to prevent neovascularization, thus improving prognosis. © 2022 Elsevier B.V., All rights reserved.
dc.identifier.doi10.5137/1019-5149.JTN.34777-21.4
dc.identifier.endpage792
dc.identifier.issn26515032
dc.identifier.issn10195149
dc.identifier.issue5
dc.identifier.pubmed35929040
dc.identifier.scopus2-s2.0-85138201359
dc.identifier.startpage786
dc.identifier.urihttps://doi.org/10.5137/1019-5149.JTN.34777-21.4
dc.identifier.urihttps://hdl.handle.net/20.500.14719/9082
dc.identifier.volume32
dc.language.isoen
dc.publisherTurkish Neurosurgical Society
dc.relation.sourceTurkish Neurosurgery
dc.subject.authorkeywordsAngiogenesis
dc.subject.authorkeywordsBevacizumab
dc.subject.authorkeywordsCornea Angiogenesis Model
dc.subject.authorkeywordsImatinib
dc.subject.authorkeywordsMeningioma
dc.subject.authorkeywordsBevacizumab
dc.subject.authorkeywordsImatinib
dc.subject.authorkeywordsRna
dc.subject.authorkeywordsAngiogenesis Inhibitors
dc.subject.authorkeywordsBevacizumab
dc.subject.authorkeywordsImatinib Mesylate
dc.subject.authorkeywordsReceptor, Platelet-derived Growth Factor Beta
dc.subject.authorkeywordsRna
dc.subject.authorkeywordsAngiogenesis Inhibitor
dc.subject.authorkeywordsBevacizumab
dc.subject.authorkeywordsImatinib
dc.subject.authorkeywordsPlatelet Derived Growth Factor Beta Receptor
dc.subject.authorkeywordsRna
dc.subject.authorkeywordsAnimal
dc.subject.authorkeywordsCornea Neovascularization
dc.subject.authorkeywordsMeningioma
dc.subject.authorkeywordsMetabolism
dc.subject.authorkeywordsNeovascularization (pathology)
dc.subject.authorkeywordsRat
dc.subject.authorkeywordsAngiogenesis Inhibitors
dc.subject.authorkeywordsAnimals
dc.subject.authorkeywordsBevacizumab
dc.subject.authorkeywordsCorneal Neovascularization
dc.subject.authorkeywordsImatinib Mesylate
dc.subject.authorkeywordsMeningeal Neoplasms
dc.subject.authorkeywordsMeningioma
dc.subject.authorkeywordsNeovascularization, Pathologic
dc.subject.authorkeywordsRats
dc.subject.authorkeywordsReceptor, Platelet-derived Growth Factor Beta
dc.subject.indexkeywordsangiogenesis inhibitor
dc.subject.indexkeywordsbevacizumab
dc.subject.indexkeywordsimatinib
dc.subject.indexkeywordsplatelet derived growth factor beta receptor
dc.subject.indexkeywordsRNA
dc.subject.indexkeywordsanimal
dc.subject.indexkeywordscornea neovascularization
dc.subject.indexkeywordsmeningioma
dc.subject.indexkeywordsmetabolism
dc.subject.indexkeywordsneovascularization (pathology)
dc.subject.indexkeywordsrat
dc.subject.indexkeywordsAngiogenesis Inhibitors
dc.subject.indexkeywordsAnimals
dc.subject.indexkeywordsBevacizumab
dc.subject.indexkeywordsCorneal Neovascularization
dc.subject.indexkeywordsImatinib Mesylate
dc.subject.indexkeywordsMeningeal Neoplasms
dc.subject.indexkeywordsMeningioma
dc.subject.indexkeywordsNeovascularization, Pathologic
dc.subject.indexkeywordsRats
dc.subject.indexkeywordsReceptor, Platelet-Derived Growth Factor beta
dc.titleAntiangiogenic Molecules Suppressed Meningioma-Induced Neovascularization: A Corneal Angiogenesis Study
dc.typeArticle
dcterms.referencesAkakin, Akin In, Endovascular treatment increases but gamma knife radiosurgery recreases angiogenic activity of arteriovenous malformations: An in vivo experimental study using a rat cornea model, Neurosurgery, 66, 1, pp. 121-129, (2010), Bitzer, Michael, Angiogenesis and brain oedema in intracranial meningiomas: Influence of vascular endothelial growth factor, Acta Neurochirurgica, 140, 4, pp. 333-340, (1998), Daşanu, Constantin A., Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs, Expert Opinion on Biological Therapy, 19, 2, pp. 99-104, (2019), Erdaǧ, Berrin, Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2, Biotechnology and Applied Biochemistry, 58, 6, pp. 412-422, (2011), Furtner, Julia, Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma, Neuro-Oncology, 18, 3, pp. 401-407, (2016), Gal-Or, Orly, Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model, Experimental Eye Research, 145, pp. 412-416, (2016), Gimbrone, Michael A., Tumor growth and neovascularization: an experimental model using the rabbit cornea, Journal of the National Cancer Institute, 52, 2, pp. 413-427, (1974), Goutagny, Stéphane, Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab, Annals of Oncology, 22, 4, pp. 990-991, (2011), Karal-Yilmaz, Okşan, Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis, Journal of Materials Science: Materials in Medicine, 24, 1, pp. 147-153, (2013), Kiliç, Kaya, Gamma knife radiosurgery inhibits angiogenesis of meningiomas: In vivo rat corneal assay, World Neurosurgery, 80, 5, pp. 598-604, (2013)
dspace.entity.typePublication
local.indexed.atScopus
person.identifier.scopus-author-id39262707100
person.identifier.scopus-author-id24170982700
person.identifier.scopus-author-id57863713200
person.identifier.scopus-author-id55318846300
person.identifier.scopus-author-id55042518500

Files

Collections

Scopus İndeksli Yayınlar Koleksiyonu